Saltar al contenido
Merck

Signatures of Dermal Fibroblasts from RDEB Pediatric Patients.

International journal of molecular sciences (2021-03-07)
Arkadii K Beilin, Nadezhda A Evtushenko, Daniil K Lukyanov, Nikolay N Murashkin, Eduard T Ambarchian, Alexander A Pushkov, Kirill V Savostyanov, Andrey P Fisenko, Olga S Rogovaya, Andrey V Vasiliev, Ekaterina A Vorotelyak, Nadya G Gurskaya
RESUMEN

The recessive form of dystrophic epidermolysis bullosa (RDEB) is a debilitating disease caused by impairments in the junctions of the dermis and the basement membrane of the epidermis. Mutations in the COL7A1 gene induce multiple abnormalities, including chronic inflammation and profibrotic changes in the skin. However, the correlations between the specific mutations in COL7A1 and their phenotypic output remain largely unexplored. The mutations in the COL7A1 gene, described here, were found in the DEB register. Among them, two homozygous mutations and two cases of compound heterozygous mutations were identified. We created the panel of primary patient-specific RDEB fibroblast lines (FEB) and compared it with control fibroblasts from healthy donors (FHC). The set of morphological features and the contraction capacity of the cells distinguished FEB from FHC. We also report the relationships between the mutations and several phenotypic traits of the FEB. Based on the analysis of the available RNA-seq data of RDEB fibroblasts, we performed an RT-qPCR gene expression analysis of our cell lines, confirming the differential status of multiple genes while uncovering the new ones. We anticipate that our panels of cell lines will be useful not only for studying RDEB signatures but also for investigating the overall mechanisms involved in disease progression.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Monoclonal Anti-Collagen, Type VII antibody produced in mouse, clone LH7.2, ascites fluid